溶瘤病毒
免疫系统
癌症研究
胶质瘤
免疫检查点
CD8型
生物
免疫疗法
细胞毒性T细胞
抗体
免疫学
生物化学
体外
作者
Dipongkor Saha,Robert L. Martuza,Samuel D. Rabkin
出处
期刊:Cancer Cell
[Cell Press]
日期:2017-08-01
卷期号:32 (2): 253-267.e5
被引量:506
标识
DOI:10.1016/j.ccell.2017.07.006
摘要
Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-like cells (GSCs). Oncolytic herpes simplex virus (oHSV) selectively replicates in cancer cells while inducing anti-tumor immunity. oHSV G47Δ expressing murine IL-12 (G47Δ-mIL12), antibodies to immune checkpoints (CTLA-4, PD-1, PD-L1), or dual combinations modestly extended survival of a mouse glioma model. However, the triple combination of anti-CTLA-4, anti-PD-1, and G47Δ-mIL12 cured most mice in two glioma models. This treatment was associated with macrophage influx and M1-like polarization, along with increased T effector to T regulatory cell ratios. Immune cell depletion studies demonstrated that CD4+ and CD8+ T cells as well as macrophages are required for synergistic curative activity. This combination should be translatable to the clinic and other immunosuppressive cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI